CompuGroup Medical (CGM) reports a strong fiscal year 2023 with significant sales growth and improved margins.

CompuGroup Medical (CGM) reports a strong fiscal year 2023 with significant sales growth and improved margins.

According to a report by www.presseportal.de, CompuGroup Medical (CGM) SE & Co. KGaA recorded a sales increase of 5% to EUR 1.19 billion for the 2023 financial year. The share of recurring revenue reached a high of 69%, underscoring the strength of the business model. Adjusted EBITDA increased by 13% to EUR 265 million, margin improved by 1.6 percentage points and adjusted earnings per share increased by 14% to EUR 2.06. CEO Michael Rauch emphasized that the company invested early on in the digitalization of the healthcare system and continues to rely on artificial intelligence.

These positive numbers indicate strong operational performance from CGM. The double-digit sales growth in the hospital segment as well as the dynamic international business, especially in the USA and Italy, show that CGM is benefiting from the digitalization trends in healthcare. The increase in adjusted EBITDA and adjusted earnings per share signal improved financial performance and efficiency of the company.

Given these numbers and CGM's clear commitment to the digitalization of healthcare, the company should be well positioned to achieve further growth. The implementation of artificial intelligence in products and processes shows that CGM is not just resting on existing successes, but is actively working on innovations to exploit the full potential of digitalized healthcare. In the long term, this could lead to a stronger competitive position and a further increase in CGM's market share.